PRTG
Portage Biotech Inc
$
8.920
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
8.960
Open
8.8989
VWAP
8.91
Vol
6.91K
Mkt Cap
19.85M
Low
8.820
Amount
61.53K
EV/EBITDA(TTM)
--
Total Shares
19.78M
EV
17.47M
EV/OCF(TTM)
--
P/S(TTM)
--
Portage Biotech Inc. is a clinical-stage immuno-oncology company. The Company is engaged in advancing therapies to improve long-term treatment, response, and quality of life in patients with cancers. The Company’s access to technologies coupled with biological mechanisms enables the identification of clinical therapies and product development strategies, which accelerate these medicines through the translational pipeline. Its adenosine antagonist platform include PORT-9 and PORT-8. PORT-9 and PORT-8 are in the preclinical stage. Its PORT-8 is a dual inhibitor of adenosine receptors 2A and 2B (A2A/A2B) to address solid tumors. Its PORT-9 is an A2B antagonist designed to treat colorectal and gastrointestinal cancers. Its iNKT Engager platform includes PORT- 3, which is in Phase I.
Show More
Valuation Metrics
The current forward P/E ratio for Portage Biotech Inc (PRTG.O) is -0.85, compared to its 5-year average forward P/E of -5.07. For a more detailed relative valuation and DCF analysis to assess Portage Biotech Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-5.07
Current PE
-0.85
Overvalued PE
2.09
Undervalued PE
-12.23
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financials
Annual
Quarterly
FY2025Q2
YoY :
-72.90%
-1.61M
Operating Profit
FY2025Q2
YoY :
-73.63%
-1.36M
Net Income after Tax
FY2025Q2
YoY :
-78.28%
-1.26
EPS - Diluted
FY2025Q2
YoY :
-100.00%
N/A
Free Cash Flow
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
PRTG News & Events
Events Timeline
2025-06-25 (ET)
2025-06-25
07:15:21
Portage regains full compliance with Nasdaq continued listing requirements
2025-06-09 (ET)
2025-06-09
06:09:16
Portage Biotech, Compedica enter mutual subscription agreement
2025-04-28 (ET)
2025-04-28
06:06:33
Portage Biotech's PORT-7 shows efficacy in mesothelioma preclinical study
Sign Up For More Events
Sign Up For More Events
News
9.5
07-25Yahoo FinancePortage Biotech Reports Results for Fiscal Year Ended March 31, 2025
9.5
06-26BenzingaWhy Worthington Steel Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket
7.0
06-25NASDAQ.COMPortage Biotech Regains Nasdaq Compliance, Maintains Listing On Capital Market
Sign Up For More News
People Also Watch
FAQ
What is Portage Biotech Inc (PRTG) stock price today?
The current price of PRTG is 8.92 USD — it has increased 2.41 % in the last trading day.
What is Portage Biotech Inc (PRTG)'s business?
What is the price predicton of PRTG Stock?
What is Portage Biotech Inc (PRTG)'s revenue for the last quarter?
What is Portage Biotech Inc (PRTG)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Portage Biotech Inc (PRTG)'s fundamentals?
How many employees does Portage Biotech Inc (PRTG). have?